Condition: Metastatic Colorectal Cancer · Sponsor: Alethia Biotherapeutics
This Phase II study will recruit 17 colorectal cancer patients with liver-dominant metastases. All recruited patients will receive Sotevtamab at a dose of 800 mg once weekly for 6 cycles combined with FOLFOX once every 2 weeks for the first 4 cycles followed by liver metastases resection surgery with or without primary cancer resection. One cycle of treatment will consist of 14 days (2 weeks).
This description comes directly from the study's public registry record.
Julie Laurin, B. Pharm, Ph.D. · 514-581-8125 · julie.laurin@alethiabio.com
Always discuss trial participation with your own doctor first.
| Centre Hospitalier de l'Université de Montréal (CHUM) | Montreal, Quebec, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06225843